ClinicalTrials.gg
CompletedNCT05050279Updated Apr 28, 2026

A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People

An Early Phase 1 interventional study of Delgocitinib capsule and Placebo capsule in Healthy, sponsored by LEO Pharma. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by LEO Pharma · Early Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this trial is to investigate the effects of delgocitinib, taken as a capsule, on the heart rhythms of healthy people, compared to a placebo.

Read the detailed description

The trial will be performed in two parts.

  • Part 1: Group 1 (dose 1 or placebo) and Group 2 (dose 2 or placebo)
  • Part 2: Group 3 (dose 3 or placebo) and Group 4 (dose 4 or placebo)

The doses in Part 2 may be adjusted depending on the results of Part 1.

Participants will be screened within 28 days of their dose. Participants will stay in the clinic from Day -1 to Day 2 (1 day postdose) and will be dosed on Day 1. A follow up phone call will take place 2 week (±2 days) after dosing.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of ≥18.0 and \<30.0 kg/m2.
  • In good health, as judged by the investigator based on: medical history, physical examination, vital sign assessment, clinical laboratory evaluations .
  • without any abnormal findings at both screening and baseline
  • No history of additional risk factors for torsades de pointes (for example, heart failure, hypokalaemia, family history of long syndrome).
  • Female subjects of and male subjects with a female partner of childbearing potential must be willing to use highlly effective methods of .

Exclusion criteria

Exclusion Criteria:

  • Any disorder which is not stable and could:

    • Affect the safety of the subject throughout the trial.
    • Influence the findings of the trial.
    • Impede the subject's ability to complete the trial.
  • Use of any medication known to prolong the /QTc interval within 3 months or 5 half-lives of the drug, whichever is longer, prior to randomisation.
  • Any medications, including St. John's wort, known to chronically alter drug absorption or elimination processes within 30 days prior to dosing.
  • Current use of combined hormone or combined hormonal replacement therapy.
  • Subjects who have smoked (use of any type of tobacco and nicotine containing products) within the last 3 months prior to screening.
  • History of chronic alcohol or drug abuse within 12 months prior to screening.
  • Receipt of any vaccine approved for SARS-CoV-2 within 4 weeks prior to baseline and/or 2 weeks after dose.
  • Receipt of live, attenuated vaccines within 4 weeks prior to baseline.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Delgocitinib placebo capsule

    Drug: Placebo capsule

  • Experimental
    Active dose 1

    Delgocitinib capsule (Dose 1)

    Drug: Delgocitinib capsule

  • Experimental
    Active dose 2

    Delgocitinib capsule (Dose 2)

    Drug: Delgocitinib capsule

  • Experimental
    Active dose 3

    Delgocitinib capsule (Dose 3)

    Drug: Delgocitinib capsule

  • Experimental
    Active dose 4

    Delgocitinib capsule (Dose 4)

    Drug: Delgocitinib capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline QTcF (ΔQTcF)

    Replicate electrocardiograms (ECGs) (10 ECG replicates) for the determination of ΔQTc interval will be extracted from the continuous digital 12-lead ECG recording

    Time frame: predose to 24 hours postdose

Secondary outcomes

  1. Placebo-corrected change from baseline QTcF (ΔΔQTcF)

    Replicate electrocardiograms (ECGs) (10 ECG replicates) for the determination of ΔΔQTc interval will be extracted from the continuous digital 12-lead ECG recording

    Time frame: predose to 24 hours postdose

  2. Change from baseline of Heart Rate (ΔHR)

    Replicate electrocardiograms (ECGs) (10 ECG replicates) for the determination of ΔHR interval will be extracted from the continuous digital 12-lead ECG recording

    Time frame: predose to 24 hours postdose

  3. Placebo-corrected, change from baseline of Heart Rate (ΔΔHR)

    Replicate electrocardiograms (ECGs) (10 ECG replicates) for the determination of ΔΔHR interval will be extracted from the continuous digital 12-lead ECG recording

    Time frame: predose to 24 hours postdose

  4. Change from baseline of Pulse Rate (ΔPR)

    Measurement of PR will be performed manually from electrocardiograms (ECGs).

    Time frame: predose to 24 hourse postdose

  5. Placebo-corrected, change from baseline of Pulse Rate (ΔΔPR)

    Measurement of PR will be performed manually from electrocardiograms (ECGs).

    Time frame: predose to 24 hours postdose

  6. Change from baseline of QRS interval (ΔQRS)

    Measurement of QRS will be performed manually from electrocardiograms (ECGs).

    Time frame: predose to 24 hours postdose

  7. Placebo-corrected, change from baseline of QRS interval (ΔΔQRS)

    Measurement of QRS will be performed manually from electrocardiograms (ECGs).

    Time frame: predose to 24 hours postdose

  8. Frequency of treatment emergent changes in T-wave morphology.

    Measurement of T-wave morphology will be performed manually

    Time frame: predose to 24 hours postdose

  9. Frequency of treatment emergent changes in U-waves presence

    Measurement of U-waves presence will be performed manually

    Time frame: predose to 24 hours postdose

  10. Categorical outliers for QTcF, HR, PR interval, and QRS duration.

    Analysis perfomed for changes in categorical outlines based on treatment emergent adverse events.

    Time frame: predose to 24 hours post-dose

  11. Number of treatment emergent adverse events

    Time frame: dosing to day 15

07

Study locations

1 site
  • Labcorp Clinical Research Unit (CRU) Ltd, Springfield House, Hyde Street,
    Leeds, LS2 9LH, United Kingdom
08

References and documents

Publications

  • Thaci D, Gooderham M, Lovato P, Madsen DE, Soehoel A, Bissonnette R. Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema. J Eur Acad Dermatol Venereol. 2025 Sep;39(9):1612-1621. doi: 10.1111/jdv.20777. Epub 2025 Jun 17. PubMed 40525591 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jan 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2021
First posted
Sep 20, 2021
StartActual
Sep 29, 2021
Primary completionActual
Jan 4, 2022
CompletionActual
Jan 4, 2022
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05050279
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Sep 20, 2021
Start date
Sep 29, 2021
Primary completion
Jan 4, 2022
Completion
Jan 4, 2022
Last update
Apr 28, 2026

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion